PANDEMİK İNFLUENZADA ANTİVİRAL TEDAVİ

1. Aok FY, Hayden FG, Dolin R. Antiviral drugs (other than antiretrovirals). In: Mandell GL,
Bennett JE, Dolin R (eds). Mandell, Douglas, and Bennett’s Principles and Practice of
Infectious Diseases. Churchill Livingstone. Philadelphhia, USA, 7th ed. 2010;565-610.
2. Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral
neuraminidase inhibitor peramivir in experimental human influenza: Randomised,
controlled trials for prophylaxis and treatment. Antivir Ther 2005; 10:901.
3. Blick TJ, Sahasrabudhe A, McDonald M, Owens IJ, Morley PJ, Fenton RJ, McKimm-
Breschkin JL. The interaction of neuraminidase and hemagglutinin mutations in influenza
virus in resistance to 4-guanidino-neu5Ac2en. Virology 1998; 246:95-103.
44
4. Biocryst Pharmaceuticals. Request for Information (RFI) ORDC-06-01 for advanced
development of antiviral agents for prophylactic/therapeutic usage during
seasonal/pandemic influenza outbreaks. 2006.
5. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza
A virus quasi species after cessation of antiviral therapy in an immunocompromised
patient. Clin Infect Dis 2002; 34:E23-E25.
6. Bui M, Whittaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of
influenza virus ribonucleoproteins. J Virol 1996; 70:8391-8401.
7. Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG. Safety and efficacy of intravenous
zanamivir in preventing experimental human influenza a virus infection. Antimicrob Agents
Chemother 1999; 4(3):1616-1620.
8. Centers for Disease Control and Prevention. Oseltamivir-Resistant Novel Influenza A
(H1N1) Virus Infection in Two Immunosuppressed Patients — Seattle, Washington, 2009.
MMWR Morb Mortal Wkly Rep 2009; 58: 893-896.
9. Centers for Disease Control and Prevention: Update: Influenza Activity: United States,
September 28, 2008-January 31, 2009. MMWR 2009; 58:115-119.
10. Centers for Disease Control and Prevention: Update: Drug susceptibility of swine-origin
influenza A (H1N1) viruses. MMWR Morb Mortal Wkly Rep 2009; 58:433-435.
11. Colman PM. Influenza virus neuraminidase: Structure, antibodies, and inhibitors. Protein
Sci 1994; 3:1687-1696.
12. Dodds L, McNeil SA, Fell DB, Allen VM, Coombs A, Scott J, MacDonald N. Impact of
influenza exposure on rates of hospital admissions and physician visits because of
respiratory illness among pregnant women. CMAJ. 2007;176(4):463-468.
13. Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A,
Poblano-Morales M, Baltazar-Torres JA, Bautista E, Martinez A, Martinez MA, Rivero E,
Valdez R, Ruiz-Palacios G, Hernández M, Stewart TE, Fowler RA. Critically Ill patients
with 2009 influenza A(H1N1) in Mexico. JAMA. 2009;302(17):1880-7.
14. Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients
receiving oseltamivir. Pharmacoepidemiol Drug Saf 2003; 12: 1-11.
15. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations
in the neuraminidase active site of influenza viruses that are resistant to 4-guanidinoneu5ac2en.
J Virol 1997; 71: 3385-3390.
16. Gubareva LG, Webster RG, Hayden FG. Comparison of the activities of zanamivir,
oseltamivir and RWJ-70201 against clinical isolates of influenza virus and neuraminidase
inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45: 3403-3408.
45
17. Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V,
Kaewchana S, Areechokechai D, Levy J, Ungchusak K. Severe human influenza infections
in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS ONE. 2009; 4:
e6051.
18. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ,
Neuzil KM, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK; Expert Panel of the
Infectious Diseases Society of America. Seasonal influenza in adults and children—
diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical
practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009;
48:1003-1032.
19. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific antiinfluenza
action of amantadine. EMBO J 1985; 4: 3021-3024.
20. Hill G, Cihlar T, Oo C, Ho ES, Prior K, Wiltshire H, Barrett J, Liu B, Ward P. The antiinfluenza
drug oseltamivir exhibits low potential to induce pharmacokinetic drug
interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metabolism
Disposition 2002; 30 :13-19.
21. Holodniy M, Penzak SR, Straight TM, Davey RT, Lee KK, Goetz MB, Raisch DW,
Cunningham F, Lin ET, Olivo N, Deyton LR. Pharmacokinetics and tolerability of oseltamivir
combined with probenecid. Antimicrob Agents Chemother 2008; 52: 3013-3021.
22. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-
Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K,
Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima
M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M,
Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura
K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya
N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. In vitro
and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009;
460: 1021-1025.
23. Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, Louie J, Sugerman DE,
Druckenmiller JK, Ritger KA, Chugh R, Jasuja S, Deutscher M, Chen S, Walker JD, Duchin
JS, Lett S, Soliva S, Wells EV, Swerdlow D, Uyeki TM, Fiore AE, Olsen SJ, Fry AM,
Bridges CB, Finelli L; 2009 Pandemic Influenza A (H1N1) Virus Hospitalizations
Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States,
April-June 2009. N Engl J Med. 2009; 361: 1935-44.
24. Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS,
Lindstrom S, Louie JK, Christ CM, Bohm SR, Fonseca VP, Ritger KA, Kuhles DJ, Eggers
P, Bruce H, Davidson HA, Lutterloh E, Harris ML, Burke C, Cocoros N, Finelli L,
MacFarlane KF, Shu B, Olsen SJ; Novel Influenza A (H1N1) Pregnancy Working Group.
H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009; 374:
451-458.
46
25. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment
on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern
Med 2003; 163: 1667-1672.
26. Khanna M, Gupta N, Gupta A, Vijayan VK. Influenza A (H1N1) 2009: a pandemic alarm.
J Biosci 2009; 34: 481-489
27. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen
MS, Mendel DB, Tai CY, Laver WG, Stevens RC. Influenza neuraminidase inhibitors
possessing a novel hydrophobic interaction in the enzyme active site: Design, synthesis,
and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza
activity. J Am Chem Soc 1997; 119:681-690.
28. Kohno S, Kida H, Mizuguchi M. A double-blind, placebo-controlled study of intravenous
peramivir in acute influenza patients. Abstract V-4154a. Interscience Conference
Antimicrobials Agents and Chemotherapeutics, Washington, DC, October 25-28, 2008.
29. Kohno S. Single-intravenous Peramivir vs. Oral Oseltamivir to Treat Acute, Uncomplicated
Influenza in the Outpatient Setting: A Phase III Randomized, Double-blind Trial. Abstract
V-537a. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA September 12-15, 2009.
30. Leung TWC, Tai ALS, Cheng PKC, Kong MSY, Lim W. Detection of an oseltamivir-resistant
pandemic influenza A/H1N1 virus in Hong Kong [letter]. J Clin Virol. 2009; 46 :298-299.
31. McClellan K, Perry CM. Oseltamivir: A review of its use in influenza. Drugs 2001; 61: 263-
283.
32. McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, Low DE; Toronto
Invasive Bacterial Diseases Network. Toronto Invasive Bacterial Diseases Network.
Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada.
Clin Infect Dis. 2007; 45: 1568-1575.
33. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ,
Bethell RC, Varghese JN. Mutations in a conserved residue in the influenza virus
neuraminidase active site decreases sensitivity to neu5acen-derived inhibitors. J
Virol 1998; 72: 2456-2462.
34. Memoli MJ, Hrabal RJ, Hassantoufighi A, Eichelberger MC, Taubenberger JK. Rapid
selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2
immunocompromised hosts. Clin Infect Dis. 2010; 50: 1252-1255.
35. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses
to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49: 4515-4520.
36. Moscona A. Oseltamivir resistance: disabling our influenza defenses. N Engl J
Med 2005; 353: 2633-2636.
47
37. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A,
Kinnersley N, Ward P. Efficacy and safety of oseltamivir in treatment of acute influenza: a
randomized controlled trial. Lancet 2000; 355: 1845-1850.
38. Oseltamivir?resistant pandemic (H1N1) 2009 influenza virus, October 2009. World Health
Organization, Weekly Epidemiol Rec, 2009, 8444: 453?458
39. Peramivir Investigator Brochure. Biocryst Pharmaceuticals, Cary, NC. 2007.
40- Rasmussen SA, Jamieson DJ, Bresee JS. Pandemic influenza and pregnant women
[editorial]. Emerg Infect Dis. 2008; 14: 95-100
41. Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut
P, Payungporn S, Poovorawan Y, Hannongbua S. Susceptibility of antiviral drugs against
2009 influenza A (H1N1) virus. Biochem Biophys Res Commun 2009; 385: 390-394
42. Shiraishi K, Mitamura K, Sakai-Tagawa Y, Goto H, Sugaya N, Kawaoka Y. High frequency
of resistant viruses harboring different mutations in amantadine-treated children with
influenza. J Infect Dis 2003; 188: 57-61
43. Sidwell RW, Bailey KW, Morrison AC. Inability to select in vivo for influenza A resistance
to the orally administered neuraminidase inhibitor RWJ-270201. Third Int Symp Resp Viral
Infections. St. Lucia, Windward Islands, 2000.
44. Sidwell RW, Smee DF, Huffman DH, Barnard DL, Bailey KW, Morrey JD, Babu YS. In
vivo influenza virus inhibitory effects of the cyclopentane neuraminidase inhibitor RWJ-
270201. Antimicrob Agents Chemother 2001; 45: 749-757
45. Speeg KV, Leighton JA, Maldonado AL. Case report: toxic delerium in a patient taking
amantadine and trimethoprim-sulfamethoxazole. Am J Med Sci 1989; 298: 410-412.
46. Sullivan SJ, Jacobson RM, Dowdle WR, Poland GA. 2009 H1N1 influenza. Mayo Clin
Proc. 2010; 85: 64-76
47. Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, Ito S. Safety of
neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding
women. CMAJ. 2009; 181: 55-58
48. Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley
N, Ward P, Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in
treating acute influenza: a randomized, controlled trial. JAMA 2000; 283: 1016-1024
49. Update on oseltamivir resistant pandemic A (H1N1) 2009 influenza virus, January 2010.
World Health Organization, Weekly Epidemiol Rec, 5 February 2010, 8506: 37?39